This week in therapeutics

Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Cancer

Cancer

Ras homolog family member J (RHOJ)

Studies in mice suggest antagonizing RHOJ could help treat cancer by disrupting the tumor vasculature. In multiple mouse models of solid tumors, Rhoj knockout decreased tumor growth, tumor vascularization and metastasis compared with Rhoj expression. A combination of a VEGF inhibitor and a fibronectin-targeting liposome carrying Rhoj-specific siRNA reduced peri- and intratumor vascularization and growth more potently than either agent alone. Next steps include identifying small molecule RHOJ antagonists.

SciBX 7(6); doi:10.1038/scibx.2014.170
Published online Feb. 13, 2014

Patent pending; available for licensing

Kim, C. et al. Cancer Cell;
published online Jan. 13, 2014;
doi:10.1016/j.ccr.2013.12.010
Contact: Gou Young Koh, Korea Advanced Institute of Science and Technology, Daejeon, South Korea
e-mail:
gykoh@kaist.ac.kr
Contact: Akiyoshi Uemura, Kobe University Graduate School of Medicine, Kobe, Japan
e-mail:
auemura@med.kobe-u.ac.jp